To the extent possible under law, AOP-Wiki has waived all copyright and related or neighboring rights to KE:1721

Event: 1721

Key Event Title

A descriptive phrase which defines a discrete biological change that can be measured. More help

Increased intestinal monitor peptide level

Short name
The KE short name should be a reasonable abbreviation of the KE title and is used in labelling this object throughout the AOP-Wiki. More help
Increased monitor peptide
Explore in a Third Party Tool

Biological Context

Structured terms, selected from a drop-down menu, are used to identify the level of biological organization for each KE. More help
Level of Biological Organization
Organ

Organ term

The location/biological environment in which the event takes place.The biological context describes the location/biological environment in which the event takes place.  For molecular/cellular events this would include the cellular context (if known), organ context, and species/life stage/sex for which the event is relevant. For tissue/organ events cellular context is not applicable.  For individual/population events, the organ context is not applicable.  Further information on Event Components and Biological Context may be viewed on the attached pdf. More help

Key Event Components

The KE, as defined by a set structured ontology terms consisting of a biological process, object, and action with each term originating from one of 14 biological ontologies (Ives, et al., 2017; https://aopwiki.org/info_pages/2/info_linked_pages/7#List). Biological process describes dynamics of the underlying biological system (e.g., receptor signalling).Biological process describes dynamics of the underlying biological system (e.g., receptor signaling).  The biological object is the subject of the perturbation (e.g., a specific biological receptor that is activated or inhibited). Action represents the direction of perturbation of this system (generally increased or decreased; e.g., ‘decreased’ in the case of a receptor that is inhibited to indicate a decrease in the signaling by that receptor).  Note that when editing Event Components, clicking an existing Event Component from the Suggestions menu will autopopulate these fields, along with their source ID and description.  To clear any fields before submitting the event component, use the 'Clear process,' 'Clear object,' or 'Clear action' buttons.  If a desired term does not exist, a new term request may be made via Term Requests.  Event components may not be edited; to edit an event component, remove the existing event component and create a new one using the terms that you wish to add.  Further information on Event Components and Biological Context may be viewed on the attached pdf. More help

Key Event Overview

AOPs Including This Key Event

All of the AOPs that are linked to this KE will automatically be listed in this subsection. This table can be particularly useful for derivation of AOP networks including the KE. Clicking on the name of the AOP will bring you to the individual page for that AOP. More help
AOP Name Role of event in AOP Point of Contact Author Status OECD Status
TI-induced AC tumors KeyEvent Arthur Author (send email) Under development: Not open for comment. Do not cite Under Development

Taxonomic Applicability

Latin or common names of a species or broader taxonomic grouping (e.g., class, order, family) that help to define the biological applicability domain of the KE.In many cases, individual species identified in these structured fields will be those for which the strongest evidence used in constructing the AOP was available in relation to this KE. More help
Term Scientific Term Evidence Link
Homo sapiens Homo sapiens Low NCBI
Macaca fascicularis Macaca fascicularis Low NCBI
Rattus norvegicus Rattus norvegicus High NCBI
Mus musculus Mus musculus High NCBI

Life Stages

An indication of the the relevant life stage(s) for this KE. More help
Life stage Evidence
All life stages High

Sex Applicability

An indication of the the relevant sex for this KE. More help
Term Evidence
Mixed High

Key Event Description

A description of the biological state being observed or measured, the biological compartment in which it is measured, and its general role in the biology should be provided. More help

Trypsin-mediated feedback regulation of pancreatic exocrine secretion is commonly found among vertebrate species.

In rats, trypsin-sensitive monitor peptide (MP), a pancreatic soluble trypsin inhibitor (TI) found in pancreatic juice that protects against trypsin-induced auto-injury [Iwai K et al, 1987; Iwai K et al, 1988; Tsuzuki S et al, 1991; Tsuzuki S et al, 1992], plays a major role in stimulating pancreatic exocrine secretion via cholecystokinin (CCK) release [Miyasaka K et al, 1989; Fushiki T et al, 1989; Miyasaka K and Funakoshi A, 1998].

MP is a peptide consisting of 61 amino acids with a molecular weight of approximately 6000 and is secreted from pancreatic acinar cells along with other pancreatic enzymes [Iwai K et al, 1987].MP is reported to have trypsin inhibitory activity [Lin YZ et al, 1990], and it forms complexes with trypsin in the empty intestine, similar to other pancreatic soluble TIs [Voet D and Voet JG, 1995], which keeps the intestinal level of free MP low. However, once the gastric contents are transported to the small intestine, secretion of the pancreatic proteases with MP are induced, where trypsin is used for protein hydrolysis, and the level of free MP is subsequently increased [Iwai K et al, 1988; Graf R, 2006]. The increased MP level stimulates CCK release from I cells lining the small intestinal mucosa via MP receptors [Liddle RA et al, 1992; Yamanishi R et al, 1993; Yamanishi R et al, 1993; Liddle RA et al, 1992], and the resulting increase in CCK stimulates exocrine secretion from the pancreas. MP secretion is simultaneously increased to stimulate CCK release further. Therefore, MP-mediated regulation of trypsin and related proteases appears to act via a positive feedback loop as long as duodenal contents remain to consume trypsin for proteolysis.

In accordance with the increased secretion of pancreatic enzymes, proteolysis of the intestinal contents lowers protein levels in the intestinal lumen, which once again lowers the intestinal level of free MP due to the excess of trypsin. CCK release is decreased in accordance with the decreased intestinal MP level, followed by a decrease in pancreatic exocrine secretion [Liddle RA, 1995; Miyasaka K and Funakoshi A, 1998].

After ingestion of raw soya flour, which contains trypsin inhibitory activity, or TIs such as camostat, TI–trypsin complexes are formed, and the intestinal level of free MP is increased to stimulate CCK release [Yamanishi R et al, 1993], increasing the blood CCK level. Increased CCK further stimulates MP as well as other pancreatic enzymes via positive feedback regulation [Liddle RA, 1995].

How It Is Measured or Detected

A description of the type(s) of measurements that can be employed to evaluate the KE and the relative level of scientific confidence in those measurements.These can range from citation of specific validated test guidelines, citation of specific methods published in the peer reviewed literature, or outlines of a general protocol or approach (e.g., a protein may be measured by ELISA). Do not provide detailed protocols. More help

No literatures that describe the methods of measuring intestinal concentration of MP are found although some authors reported the isolation and measurement of MP from synthesis reaction solution, pancreas or pancreatic juice.

Synthesized crude peptides were eluted through gel filtration chromatography. PSTI-I-specific peak was confirmed by mas spectrometric measurement and analytical HPLC was performed [Graf R et al, 2003].

In rats fed control and high protein diets, zymogen granules were isolated and concentrations  of MP and PSTI-II in zymogen granules can be determined by HPLC [Tsuzuki S et al, 1991].

Rat anionic trypsinogen and a pancreatic secretory trypsin inhibitor were purified from the pure pancreatic juice of rats by reverse-phase HPLC [Iwai K et al, 1987].

Domain of Applicability

A description of the scientific basis for the indicated domains of applicability and the WoE calls (if provided).  More help

Feedback regulation of pancreatic enzyme secretion mediated by trypsin-sensitive intestinal peptides other than MP has been reported in mammals. Such peptides include luminal CCK-releasing factors (LCRFs) secreted by duodenal mucosal cells in response to intestinal diet in some mammalian species including rats, pigs (diazepam-binding inhibitor) and humans [Miyasaka K and Funakoshi A, 1998; Wang Y, 2002; Wang BJ and Cui ZJ, 2007]. In humans, different from rodents, LCRF is not secreted spontaneously in the intestine, however luminal amino acids and fatty acids were reported to induce CCK release [Liddle RA, 1997].

MP is one of pancreatic soluble TIs (PSTIs), which are found in the pancreatic juice of many mammalian species including pigs, dogs, and humans [Greene LJ et al, 1968; Pubols MH et al, 1974; Eddeland A and Ohlsson K, 1976; Kikuchi N et al, 1985]. Secreted PSTIs bind tightly to trypsin to protect against trypsin-induced auto-injury in the pancreas and intestinal tracts [Voet D and Voet JG, 1995].

In rats, two types of PSTIs have been isolated: MP (or PSTI-I) and PSTI-II [Tsuzuki S et al, 1991; Tsuzuki S et al, 1992]. Both are similar in amino acid sequence; however, the former directly stimulates CCK release from intestinal CCK I cells via their surface MP receptors [Yamanishi R et al, 1993], whereas the latter does not [Guan D et al, 1990].

Human PSTIs do not directly stimulate CCK release from intestinal mucosal cells [Miyasaka K et al, 1989], and no PSTI except MP has been reported to stimulate CCK release.

References

List of the literature that was cited for this KE description. More help

 1.    Eddeland A, Ohlsson K: Purification of canine pancreatic secretory trypsin inhibitor and interaction in vitro with complexes of trypsin-alpha-macroglobulin.. Scand J Clin Lab Invest 36:815-820,1976

 2.    Fushiki T, Kajiura H, Fukuoka S, Kido K, Semba T, Iwai K: Evidence for an intraluminal mediator in rat pancreatic enzyme secretion: reconstitution of the pancreatic response with dietary protein, trypsin and the monitor peptide.. J Nutr 119:622-627,1989

 3.    Graf R, Klauser S, Fukuoka SI, Schiesser M, Bimmler D: The bifunctional rat pancreatic secretory trypsin inhibitor/monitor peptide provides protection against premature activation of pancreatic juice. Pancreatology 3:195-206,2003

 4.    Graf R, Bimmler D: Biochemistry and biology of SPINK-PSTI and monitor peptide.. Endocrinol Metab Clin North Am 35:333-43, ix,2006

5.  Greene LJ, DiCarlo JJ, Sussman AJ, Bartelt DC: Two trypsin inhibitors from porcine pancreatic juice. J Biol Chem 243:1804-1815,1968

 6.    Guan D, Ohta H, Tawil T, Liddle RA, Green GM: CCK-releasing activity of rat intestinal secretion: effect of atropine and comparison with monitor peptide. Pancreas 5:677-684,1990

 7.    Iwai K, Fukuoka S, Fushiki T, Tsujikawa M, Hirose M, Tsunasawa S, Sakiyama F: Purification and sequencing of a trypsin-sensitive cholecystokinin-releasing peptide from rat pancreatic juice. Its homology with pancreatic secretory trypsin inhibitor.. J Biol Chem 262:8956-8959,1987

 8.    Iwai K, Fushiki T, Fukuoka S: Pancreatic enzyme secretion mediated by novel peptide: monitor peptide hypothesis. Pancreas 3:720-728,1988

 9.    Kikuchi N, Nagata K, Yoshida N, Ogawa M: The multiplicity of human pancreatic secretory trypsin inhibitor. J Biochem 98:687-694,1985

10.    Liddle RA, Misukonis MA, Pacy L, Balber AE: Cholecystokinin cells purified by fluorescence-activated cell sorting respond to monitor peptide with an increase in intracellular calcium. Proc Natl Acad Sci U S A 89:5147-5151,1992

11.    Liddle RA: Regulation of cholecystokinin secretion by intraluminal releasing factors. Am J Physiol 269:G319-27,1995

12.    Liddle RA: Cholecystokinin cells. Annu Rev Physiol 59:221-242,1997

13.    Lin YZ, Isaac DD, Tam JP: Synthesis and properties of cholecystokinin-releasing peptide (monitor peptide), a 61-residue trypsin inhibitor. Int J Pept Protein Res 36:433-439,1990

14.    Miyasaka K, Nakamura R, Funakoshi A, Kitani K: Stimulatory effect of monitor peptide and human pancreatic secretory trypsin inhibitor on pancreatic secretion and cholecystokinin release in conscious rats. Pancreas 4:139-144,1989

15.    Miyasaka K, Funakoshi A: Luminal feedback regulation, monitor peptide, CCK-releasing peptide, and CCK receptors. Pancreas 16:277-283,1998

16.    Pubols MH, Bartelt DC, Greene LJ: Trypsin inhibitor from human pancreas and pancreatic juice. J Biol Chem 249:2235-2242,1974

17.    Tsuzuki S, Fushiki T, Kondo A, Murayama H, Sugimoto E: Effect of a high-protein diet on the gene expression of a trypsin-sensitive, cholecystokinin-releasing peptide (monitor peptide) in the pancreas. Eur J Biochem 199:245-252,1991

18.    Tsuzuki S, Miura Y, Fushiki T, Oomori T, Satoh T, Natori Y, Sugimoto E: Molecular cloning and characterization of genes encoding rat pancreatic cholecystokinin (CCK)-releasing peptide (monitor peptide) and pancreatic secretory trypsin inhibitor (PSTI). Biochim Biophys Acta 1132:199-202,1992

19.    Voet D, Voet JG: Biochemistry (2nd ed.). John Wiley & Sons (pp) 396-400,1995

20.    Wang Y, Prpic V, Green GM, Reeve JR Jr, Liddle RA: Luminal CCK-releasing factor stimulates CCK release from human intestinal endocrine and STC-1 cells.. Am J Physiol Gastrointest Liver Physiol 282:G16-22,2002

21.    Wang BJ, Cui ZJ: How does cholecystokinin stimulate exocrine pancreatic secretion? From birds, rodents, to humans. Am J Physiol Regul Integr Comp Physiol 292:R666-78,2007

22.    Yamanishi R, Kotera J, Fushiki T, Soneda T, Iwanaga T, Sugimoto E: Characteristic and localization of the monitor peptide receptor. Biosci Biotechnol Biochem 57:1153-1156,1993

23.    Yamanishi R, Kotera J, Fushiki T, Soneda T, Saitoh T, Oomori T, Satoh T, Sugimoto E: A specific binding of the cholecystokinin-releasing peptide (monitor peptide) to isolated rat small-intestinal cells. Biochem J 291 ( Pt 1):57-63,1993